[35] further validated the presence of TPM3‐ALK fusions in RCC and significantly advanced the field by demonstrating that ALK inhibitors show promising efficacy against ALK‐rearranged RCC in their study, opening new avenues for targeted therapies. Here, TPM3 is linked to renal cell carcinoma.